

CLAIMS

1. A cell which comprises a chimeric antigen receptor (CAR) and a truncated protein which comprises an SH2 domain from a protein which binds a phosphorylated immunoreceptor tyrosine-based inhibition motif (ITIM) but lacks a phosphatase domain.
- 5 2. A cell according to Claim 1, in which the signal transduction modifying protein is a truncated protein which comprises an PTPN6 SH2 but lacks a PTPN6 phosphatase domain.
3. A cell according to Claim 1, in which the signal transduction modifying protein is a truncated protein which comprises a SHP-2 SH2 domain but lacks a SHP-2 phosphatase domain.
- 10 4. A nucleic acid construct, which comprises:
 - a first nucleic acid sequence encoding a chimeric antigen receptor; and
 - a second nucleic acid sequence encoding a truncated protein as defined in any preceding claim.
5. A vector which comprises a nucleic acid construct according to Claim 4.
- 15 6. A vector according to Claim 5, which is a retroviral or lentiviral vector.
7. A pharmaceutical composition comprising a plurality of cytolytic immune cells according Claim 1, 2 or 3.
8. A pharmaceutical composition according to Claim 7 for use in treating a disease.
9. A pharmaceutical composition for use according to Claim 8, in which:
 - 20 (i) a cell containing sample is isolated from a subject;
 - (ii) the cells are transduced or transfected with a nucleic acid construct according to Claim 4 or a vector according to Claim 5 or 6; and
 - (iii) the cells from (ii) are to be administered to the subject.
10. Use of a pharmaceutical composition according to Claim 7 in the manufacture of a
 - 25 medicament for the treatment and/or prevention of a disease.
11. A pharmaceutical composition for use according to Claim 8 or 9 or a use according to Claim 10, in which the disease is cancer.

12. A method for making a cell according to Claim 1, 2 or 3, which comprises the step of introducing: a nucleic acid construct according to Claim 4 or a vector according to Claim 5 or 6, into the cell.

13. A method according to Claim 12, in which the cell is from a sample isolated from a
5 subject.